CO6480934A2 - Ácido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil)fenil]metil](2-metil-2h-tetrazol-5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-bezazepin-1-il]-ciclohexancarboxílico. - Google Patents

Ácido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil)fenil]metil](2-metil-2h-tetrazol-5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-bezazepin-1-il]-ciclohexancarboxílico.

Info

Publication number
CO6480934A2
CO6480934A2 CO11177215A CO11177215A CO6480934A2 CO 6480934 A2 CO6480934 A2 CO 6480934A2 CO 11177215 A CO11177215 A CO 11177215A CO 11177215 A CO11177215 A CO 11177215A CO 6480934 A2 CO6480934 A2 CO 6480934A2
Authority
CO
Colombia
Prior art keywords
methyl
tetrazol
trans
bis
phenyl
Prior art date
Application number
CO11177215A
Other languages
English (en)
Spanish (es)
Inventor
Xinchao Chen
Scott Alan Frank
David Michael Remick
Steven Wayne Pedersen
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42352717&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6480934(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO6480934A2 publication Critical patent/CO6480934A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CO11177215A 2009-06-30 2011-12-22 Ácido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil)fenil]metil](2-metil-2h-tetrazol-5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-bezazepin-1-il]-ciclohexancarboxílico. CO6480934A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22170809P 2009-06-30 2009-06-30

Publications (1)

Publication Number Publication Date
CO6480934A2 true CO6480934A2 (es) 2012-07-16

Family

ID=42352717

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11177215A CO6480934A2 (es) 2009-06-30 2011-12-22 Ácido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil)fenil]metil](2-metil-2h-tetrazol-5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-bezazepin-1-il]-ciclohexancarboxílico.

Country Status (37)

Country Link
US (2) US8329688B2 (enExample)
EP (1) EP2448933B1 (enExample)
JP (1) JP5689875B2 (enExample)
KR (1) KR101404893B1 (enExample)
CN (1) CN102639528B (enExample)
AR (1) AR077208A1 (enExample)
AU (1) AU2010266537B2 (enExample)
BR (1) BRPI1011931A2 (enExample)
CA (1) CA2764425C (enExample)
CL (1) CL2011003263A1 (enExample)
CO (1) CO6480934A2 (enExample)
CR (1) CR20110669A (enExample)
DK (1) DK2448933T3 (enExample)
DO (1) DOP2011000405A (enExample)
EA (1) EA020600B1 (enExample)
EC (1) ECSP11011551A (enExample)
ES (1) ES2435293T3 (enExample)
GT (1) GT201100321A (enExample)
HR (1) HRP20130950T1 (enExample)
IL (1) IL216655A (enExample)
JO (1) JO2867B1 (enExample)
MA (1) MA33385B1 (enExample)
ME (1) ME01606B (enExample)
MX (1) MX2011014024A (enExample)
MY (1) MY157121A (enExample)
NZ (1) NZ596820A (enExample)
PE (1) PE20120538A1 (enExample)
PL (1) PL2448933T3 (enExample)
PT (1) PT2448933E (enExample)
RS (1) RS52988B (enExample)
SG (1) SG177413A1 (enExample)
SI (1) SI2448933T1 (enExample)
TN (1) TN2011000638A1 (enExample)
TW (1) TWI450896B (enExample)
UA (1) UA109409C2 (enExample)
WO (1) WO2011002696A1 (enExample)
ZA (1) ZA201108707B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080269284A1 (en) * 2004-06-24 2008-10-30 Eli Lilly And Company Compounds and Methods for Treating Dyslipidemia
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
CN103648495A (zh) 2011-07-08 2014-03-19 诺华股份有限公司 在高甘油三酯对象中治疗动脉粥样硬化的方法
CN103958501B (zh) * 2012-07-16 2016-08-17 上海恒瑞医药有限公司 苯并七元杂环类衍生物、其制备方法及其在医药上的应用
AU2014213125B2 (en) 2013-01-31 2016-06-02 Chong Kun Dang Pharmaceutical Corp. Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as CETP inhibitors
CN105017085B (zh) * 2014-04-28 2018-06-29 中国科学院上海药物研究所 一类kcnq钾通道激动剂、其制备方法和用途
WO2016016157A1 (en) 2014-07-30 2016-02-04 F. Hoffmann-La Roche Ag Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent
TWI691331B (zh) 2014-09-26 2020-04-21 日商興和股份有限公司 脂質異常症治療劑
CN108456213B (zh) * 2017-02-22 2021-01-15 浙江九洲药业股份有限公司 一种3-氟-4-羟基环己烷羧酸酯的制备方法
WO2025093129A1 (en) 2023-11-01 2025-05-08 Newamsterdam Pharma B.V. Treatment and prevention of age-related macular degeneration using a cetp inhibitor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4948639B1 (enExample) 1970-12-15 1974-12-23
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
CO5271716A1 (es) 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
CA2445623A1 (en) * 2001-04-30 2002-11-07 Pfizer Products Inc. Methods for preparing cetp inhibitors
US7332514B2 (en) * 2002-08-30 2008-02-19 Japan Tobacco Inc. Dibenzylamine compound and medicinal use thereof
PL376156A1 (en) * 2002-10-04 2005-12-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
JP2006523218A (ja) * 2003-03-04 2006-10-12 高砂香料工業株式会社 光学活性アミン類の製造方法
US20040204450A1 (en) * 2003-03-28 2004-10-14 Pfizer Inc Quinoline and quinoxaline compounds
WO2005037796A1 (en) * 2003-10-08 2005-04-28 Eli Lilly And Company Compounds and methods for treating dyslipidemia
BRPI0508966A (pt) 2004-03-26 2007-08-21 Lilly Co Eli composto, composição farmacêutica, e, uso de um composto
CN1972927A (zh) * 2004-06-24 2007-05-30 伊莱利利公司 用于治疗血脂障碍的化合物和方法
US20080269284A1 (en) 2004-06-24 2008-10-30 Eli Lilly And Company Compounds and Methods for Treating Dyslipidemia
US7700774B2 (en) * 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸

Also Published As

Publication number Publication date
CR20110669A (es) 2012-03-16
CA2764425C (en) 2015-01-06
IL216655A (en) 2015-02-26
SI2448933T1 (sl) 2013-11-29
HRP20130950T1 (hr) 2013-11-22
ME01606B (me) 2014-09-20
RS52988B (sr) 2014-02-28
TN2011000638A1 (en) 2013-05-24
DK2448933T3 (da) 2013-10-07
AU2010266537B2 (en) 2013-04-18
UA109409C2 (ru) 2015-08-25
ES2435293T3 (es) 2013-12-18
TW201113275A (en) 2011-04-16
KR20120027426A (ko) 2012-03-21
BRPI1011931A2 (pt) 2016-04-19
PT2448933E (pt) 2013-10-29
MA33385B1 (fr) 2012-06-01
PL2448933T3 (pl) 2014-01-31
GT201100321A (es) 2012-11-15
IL216655A0 (en) 2012-02-29
DOP2011000405A (es) 2012-01-15
AR077208A1 (es) 2011-08-10
JP5689875B2 (ja) 2015-03-25
CN102639528A (zh) 2012-08-15
EP2448933B1 (en) 2013-08-28
MY157121A (en) 2016-05-13
KR101404893B1 (ko) 2014-06-20
NZ596820A (en) 2013-07-26
JO2867B1 (en) 2015-03-15
CN102639528B (zh) 2014-07-16
US20100331309A1 (en) 2010-12-30
WO2011002696A1 (en) 2011-01-06
ZA201108707B (en) 2013-05-29
US8299060B2 (en) 2012-10-30
US8329688B2 (en) 2012-12-11
JP2012532106A (ja) 2012-12-13
ECSP11011551A (es) 2012-01-31
EA020600B1 (ru) 2014-12-30
US20120058990A1 (en) 2012-03-08
CA2764425A1 (en) 2011-01-06
CL2011003263A1 (es) 2012-07-27
EP2448933A1 (en) 2012-05-09
SG177413A1 (en) 2012-02-28
TWI450896B (zh) 2014-09-01
PE20120538A1 (es) 2012-05-09
EA201270099A1 (ru) 2012-05-30
AU2010266537A1 (en) 2012-02-02
MX2011014024A (es) 2012-04-20

Similar Documents

Publication Publication Date Title
ECSP11011551A (es) Ácido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil)fenil]metil] (2-metil-2h-tetrazol-5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il]metil]-ciclohexancarboxílico
MY153985A (en) Aminotriazole derivatives as alx agonists
TN2012000371A1 (en) Pyrazole compounds as crth2 antagonists
MX342440B (es) Derivados fluorados de aminotriazol.
JP2011030727A5 (enExample)
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
MY153921A (en) Aminopyrazole derivatives
WO2008130678A3 (en) Rosuvastatin intermediates and process for the preparation of rosuvastatin
MX2010001742A (es) Nuevos derivados de piperazina-amida.
MX342153B (es) Compuestos para el tratamiento y profilaxis de enfermedad por el virus sincitial respiratorio.
UA105057C2 (uk) Композиція 1-[2-(2,4-диметилфенілсульфаніл)феніл]-піперазину
IN2012DN00765A (enExample)
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
MX2017016862A (es) Composicion farmaceutica estable para administracion oral.
CO6721028A2 (es) Acoplamientos eficientes de péptido y su uso en la síntesis y aislamiento de una sal trisódica de ciclopenta (g) quinazolina
PE20120249A1 (es) Compuestos etanaminicos
AR083322A1 (es) Compuesto (3-{[{4-[4-amino-2-(etoximetil)-1h-imidazol[4,5-c]quinolin-1-il]butil}(n,n-dietilglicil)amino]metil}fenil)acetato de metilo
CY1114514T1 (el) Τrανs-4-[[(5s)-5-[[[3,5-δις(τριφθορομεθυλ)φαινυλ]μεθυλ](2-μεθυλ-2η-τετραζολ-5-υλ)αμινο]-2,3,4,5-τετραϋδρο-7,9-διμεθυλ-1η-1-βενζαζεπιν-1 -υλ]μεθυλ]-κυκλοεξανο-καρβοξυλικο οξυ
CR20160172A (es) Ácido {4-[5-(3-cloro-fenoxi)-oxazolo[5,4-d]pirimidin-2-il]-2,6-dimetil-fenoxi}acético para su uso en la prevención o el tratamiento de la lesión renal aguda
BR112014013723A8 (pt) formas cristalinas da [(s)-1-carbamoil-2-(fenil-pirimidin-2-il-amino)-etil]-amida do ácido 2-(2-metil-amino-pirimidin-4-il)-1h-indol-5-carboxílico
HN2011003208A (es) Acido trans-4-[[(5s)-[[[3,5-bis(trifluorometil)fenil]metil](2-metil-2h-tetrazol-5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il]metil-ciclohexancarboxilico
TH115567A (th) ทรานส์-4-[[(5s)-5-[[[3,5-บิส(ไทรฟลูออโรเมธิล)เฟนิล]เมธิล](2-เมธิล-2h-เททราโซล-5-อิล)อะมิโน]-2,3,4,5-เททราไฮโดร-7,9-ไดเมธิล-1h-1-เบนแซซีพิน-1-อิล]เมธิล]-ไซโคลเฮกเซนคาร์บอกซิลิค แอซิด
CU20090143A7 (es) Derivados de ciclohexil-amida del ácido aril-carboxílico
UY31988A (es) Compuestos de pirimidinilsulfonamida para utilizar en el tratamiento de una enfermedad mediada por quimiocina
UA35751U (ru) Применение препарата "кристалл-900" в виде дезинфицирующего средства в рыбоводстве

Legal Events

Date Code Title Description
FG Application granted